Acadia Pharma (ACAD) Tops Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Acadia Pharma (ACAD) Tops Q1 EPS by 12c

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

May 4, 2018 7:30 AM EDT

Strong Performance for NUPLAZID® in First Quarter 2018

First Quarter Net Sales Grew to $48.9 Million, Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17

ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2018.

NUPLAZID delivered strong performance in the... More